2018 Kern Lipid Conference

2018年科恩脂质会议

• 批准号: 9610114
• 负责人: Robert H Eckel
• 金额: $ 1.95万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-07-01 至 2019-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9610114
• 关键词: ATP Citrate (pro-S)-Lyase; Academia; Acetates; Acetyl-CoA Carboxylase; Acids; Address; Adipocytes; Antitumor Response; Atherosclerosis; Award; Basic Science; Blood capillaries; CD8-Positive T-Lymphocytes; California; Cells; Cellular Metabolic Process; Cholesterol Homeostasis; Clinical Research; Computer Simulation; Disease; Doctor of Philosophy; Endothelial Cells; Endothelium; Epigenetic Process; Explosion; FRAP1 gene; Faculty; Family suidae; Fatty Acids; Fatty Liver; Fostering; Genetic; Genomics; Goals; Health; Hepatic; Hepatocyte; Histone Acetylation; Homeostasis; Human; Immune; Immune system; Immunity; Industry; Inflammatory; Institutes; Insulin; Insulin Receptor; International; Investigation; Ketone Bodies; LDL Cholesterol Lipoproteins; Lead; Lipids; Liver; Low Density Lipoprotein Receptor; Malignant Neoplasms; Maps; Massachusetts; Medicine; Metabolic; Metabolic Diseases; Metabolic Pathway; Metabolism; Minnesota; Molecular; Mus; Muscle; Muscle Cells; Natural Immunity; New York; Nutrient; Obesity; Ontario; Oral; Organ; Participant; Pathway interactions; Patients; Pennsylvania; Permeability; Phenotype; Plasma; Process; Regulation; Research; Research Personnel; Role; Safety; Science; Scientist; Signal Transduction; Skeletal Muscle; Source; System; T-Lymphocyte; Technology; Therapeutic; Therapeutic Uses; Time; Tissues; Translational Research; Triglycerides; Universities; Validation; Vascular Endothelial Growth Factors; Vasculitis; Warburg Effect; Washington; authority; base; bench to bedside; blood glucose regulation; body system; cancer therapy; cardiometabolism; career; detection of nutrient; improved; inhibitor/antagonist; insight; insulin sensitivity; lectures; lipid biosynthesis; lipid metabolism; lipid transport; medical schools; meetings; member; metabolomics; new therapeutic target; novel; novel strategies; novel therapeutic intervention; novel therapeutics; posters; programs; symposium; therapeutic target; translational scientist; translational study; ATP Citrate (pro-S)-Lyase; Academia; Acetates; Acetyl-CoA Carboxylase; Acids; Address; Adipocytes; Antitumor Response; Atherosclerosis; Award; Basic Science; Blood capillaries; CD8-Positive T-Lymphocytes; California; Cells; Cellular Metabolic Process; Cholesterol Homeostasis; Clinical Research; Computer Simulation; Disease; Doctor of Philosophy; Endothelial Cells; Endothelium; Epigenetic Process; Explosion; FRAP1 gene; Faculty; Family suidae; Fatty Acids; Fatty Liver; Fostering; Genetic; Genomics; Goals; Health; Hepatic; Hepatocyte; Histone Acetylation; Homeostasis; Human; Immune; Immune system; Immunity; Industry; Inflammatory; Institutes; Insulin; Insulin Receptor; International; Investigation; Ketone Bodies; LDL Cholesterol Lipoproteins; Lead; Lipids; Liver; Low Density Lipoprotein Receptor; Malignant Neoplasms; Maps; Massachusetts; Medicine; Metabolic; Metabolic Diseases; Metabolic Pathway; Metabolism; Minnesota; Molecular; Mus; Muscle; Muscle Cells; Natural Immunity; New York; Nutrient; Obesity; Ontario; Oral; Organ; Participant; Pathway interactions; Patients; Pennsylvania; Permeability; Phenotype; Plasma; Process; Regulation; Research; Research Personnel; Role; Safety; Science; Scientist; Signal Transduction; Skeletal Muscle; Source; System; T-Lymphocyte; Technology; Therapeutic; Therapeutic Uses; Time; Tissues; Translational Research; Triglycerides; Universities; Validation; Vascular Endothelial Growth Factors; Vasculitis; Warburg Effect; Washington; authority; base; bench to bedside; blood glucose regulation; body system; cancer therapy; cardiometabolism; career; detection of nutrient; improved; inhibitor/antagonist; insight; insulin sensitivity; lectures; lipid biosynthesis; lipid metabolism; lipid transport; medical schools; meetings; member; metabolomics; new therapeutic target; novel; novel strategies; novel therapeutic intervention; novel therapeutics; posters; programs; symposium; therapeutic target; translational scientist; translational study

Abstract: Since its inception in 1985, the goals of the Kern Lipid Conference have been to promote metabolic science and increase understanding of metabolic pathobiology. The conference strives to provide an inclusive, open forum for established and young emerging scientists from academia and industry. The 2018 Kern Lipid Conference chaired by Nada Abumrad, Susan Kaech and Roger Newton will have as theme “Metabolic Regulation of Immunity, Cardio-metabolic Disease, and Cancer: New Therapeutic Approaches.” The 2018 conference's goal is to provide a dynamic interactive process that leads to novel insights into disease mechanisms involving metabolic reprogramming across organs. Specifically nutrient sensing and metabolic remodeling by immune and endothelial cells/systems but also by liver, muscle and adipose cells/tissues will be examined with a focus on pathways that have the potential to lead to new therapies. The program will cover basic and translational science targeting novel therapeutics that benefit patients with dysfunctional immune systems, cardio-metabolic disorders or that improve efficacy and safety of cancer treatments. Three daily sessions with 25 confirmed speakers will be followed by three evening poster sessions. Breaks, lunches and a closing dinner on the premises promote interactions between participants. Idea exchange is maximized by allocating ample time for questions after didactic presentations and through fostering discussion by session chairs and other attending Kern board members. The Conference traditionally attracts early career scientists (~40%) and established scholars as well as creative scientists from industry. Participation of young scientists is strongly promoted by including them among the invited speakers; in 2018, 11 of the invited speakers are early careers investigators with two young investigators to be selected as recipients of the competitive prestigious awards, David L Williams and Roger Davis Lectureships. The setting and meeting format which facilitate interaction and discussion, the confirmed participation of internationally recognized authorities (e.g. David Sabatini, Reuben Shaw, Peter Carmeliet) inclusion of young emerging stars (e.g. Kathryn Wellen, Jason Locasale, Lydia Lynch) and translational researchers (Gregory Steinberg, Jay Horton), make it likely that novel insights into disease mechanisms and therapeutic approaches for immune and cardio-metabolic Disease and Cancer will emerge from the 2018 Conference.

抽象的： 自1985年成立以来，科恩脂质会议的目标一直是促进代谢科学 以及对代谢病理学的不断理解。会议努力提供包容性的开放 来自学术界和工业的成熟和新兴科学家的论坛。 2018 Kern Lipid 由Nada Abumrad，Susan Kaech和Roger Newton主持的会议将作为主题“代谢 免疫，心脏代谢疾病和癌症的调节：新的治疗方法。 2018年会议的目标是提供一个动态的互动过程，从而导致对疾病的新见解 涉及跨器官的代谢重编程的机制。特别是营养感和代谢 通过免疫和内皮细胞/系统进行重塑，以及肝脏，肌肉和脂肪细胞/组织的重塑 检查的重点是有可能导致新疗法的途径。该程序将涵盖 基本和翻译的科学针对新疗法，使免疫功能失调的患者受益 系统，心脏代谢性疾病或提高癌症治疗的效率和安全性。每天三 有25位演讲者的会议将进行三个晚上的海报会议。休息，午餐和 在场所关闭晚餐促进参与者之间的互动。想法交换是通过最大化的 在教学演示后和通过会议促进讨论后，分配充足的时间进行问题 椅子和其他参加克恩董事会成员。传统上，会议吸引了早期的职业科学家 （〜40％）并建立了学者以及工业的创意科学家。年轻科学家的参与是 通过将他们包括在受邀的演讲者中来强烈促进； 2018年，有11位受邀演讲者很早就 两名年轻调查员的职业人士调查员被选为竞争声誉的接受者 David L Williams和Roger Davis演讲奖。设置和会议格式哪种设施 互动和讨论，是国际认可的当局的确认参与（例如大卫 萨巴蒂尼（Sabatini），鲁本·肖（Reuben Shaw），彼得·卡梅利特（Peter Carmeliet））包括年轻新兴星（例如，凯瑟琳·韦伦 Locasale，Lydia Lynch）和翻译研究人员（Gregory Steinberg，Jay Horton）使这是小说 对免疫和心替代疾病的疾病机制和治疗方法的见解以及 癌症将来自2018年会议。